Heffter Research Tag

22 Dec

Posted at 09:52h in Blog
0 Likes

With Phase 2 studies on cancer-related depression and anxiety now complete, Heffter is excited to investigate other conditions that might be successfully treated with psilocybin.

Drawing on the scientific expertise and longstanding partnership of the world’s leading investigators of psychedelics, Heffter mentors the next generation of psilocybin researchers and therapists, vets new approaches, supports proof-of-concept studies, and gathers the evidence base for therapeutic treatments that, pending FDA approval, will be available to patients in need.

01 Dec

Posted at 06:31h in Blog
0 Likes

Two randomized controlled trials published today in The Journal of Psychopharmacology report unprecedented findings on the use of psilocybin to dramatically reduce anxiety, depression and existential distress in cancer patients.

These two studies — reviewed and funded by the Heffter Research Institute and conducted by the NYU School of Medicine and Johns Hopkins University — showed that a single dose of psilocybin, in conjunction with psychotherapy, produced rapid, robust and enduring (for more than six months) antianxiety and antidepressant effects in patients with life-threatening cancer diagnoses.

“These findings, the most profound to date in the medical use of psilocybin, indicate it could be more effective at treating serious psychiatric diseases than traditional pharmaceutical approaches, and without having to take a medication every day,” said Heffter Medical Director George Greer.